ArticleInsights into imaging2025
Bronchial wall T2w MRI signal as a new imaging biomarker of severe asthma.
Article in Insights into imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03089346 (Assessment of Bronchial Thickness Using MRI in Asthma), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Assessment of Bronchial Thickness Using MRI in Asthma
Who cites it
2 citing papers in PubMed.
- Bronchial Wall T2-Weighted MRI Signal: An Emerging Investigational Non-Ionizing Imaging Biomarker in Severe Asthma.Biomedicines · 2026Article
- Highlights from the Italian National Congress of Imaging in Pulmonology 2025: fostering implementation of advanced technologies for precision patient-centered care.Multidisciplinary respiratory medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectivesSevere asthma patients are prone to severe exacerbations with a need of hospital admission increasing the economic burden on healthcare systems. T2w lung MRI was found to be useful in the assessment of bronchial inflammation. The main goal of this study is to compare quantitative MRI T2 signal bronchial intensity between patients with severe and non-severe asthma.
methodsThis is an ancillary study of a prospective single-center study (NCT03089346). We assessed the mean T2 intensity MRI signal of the bronchial wall area (BrWall_T2-MIS) in 15 severe and 15 age and sex-matched non-severe asthmatic patients. They also have had pulmonary function tests (PFTs), fractional exhaled nitric oxide (FeNO) and blood eosinophils count (Eos). Comparisons between the two groups were performed using Student's t-test. Correlations were assessed using Pearson coefficients. Reproducibility was assessed using intraclass correlation coefficient and Bland-Altman analysis.
resultsBrWall_T2-MIS was higher in severe than in non-severe asthma patients (74 ± 12 vs 49 ± 14; respectively p < 0.001). BrWall_T2-MIS showed a moderate inverse correlation with PFTs in the whole cohort (r = -0.54, r = -0.44 for FEV1(%pred) and FEV1/FVC respectively, p ≤ 0.01) and in the severe asthma group (r = -0.53, r = -0.44 for FEV1(%pred) and FEV1/FVC respectively, p ≤ 0.01). Eos was moderately correlated with BrWall_T2-MIS in severe asthma group (r = 0.52, p = 0.047). Reproducibility was almost perfect with ICC = 0.99 and mean difference in Bland-Altman analysis of -0.15 [95% CI = -0.48-0.16].
conclusionQuantification of bronchial wall T2w signal intensity appears to be able to differentiate severe from non-severe asthma and correlates with obstructive PFTs' parameters and inflammatory markers in severe asthma. CRITICAL RELEVANCE STATEMENT: The development of non-ionizing imaging biomarkers could play an essential role in the management of patients with severe asthma in the current era of biological therapies. KEY POINTS: Severe asthma exhibits severe exacerbations with a high burden on healthcare systems. T2w bronchial wall signal intensity is related to inflammatory biomarker in severe asthma. T2w MRI may represent a non-invasive tool to follow up severe asthma patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.